mechanism of glp 1 receptor agonists Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Frontiers | Glucagon-like peptide-1 receptor

Initially, the team at Novo considered several different approaches, but opted to make a more stable version of GLP-1(7-37)

Recommendations for initial up-titration (Figure 2) All GLP-1 RAs developed to date have been designed for standardized dosage recommendations applicable to most if not all patients

Beyond quantitative preservation, maintaining skeletal muscle function, including strength and metabolic capacity, remains a critical therapeutic goal in ensuring long-term health outcomes

The Study of Tirzepatide (LY3298176) in Participants With Obesity (SURMOUNT-1) trial found that tirzepatide at 15 mg per week taken over 72 weeks reduced body weight by 20.9% in those with obesity but without diabetes [9]

Combining two dual agonists would be redundant and dangerous